Oncogenic FGFR3 gene fusions in bladder cancer

Human Molecular Genetics

Volumn 22, Issue 4, 2013, Pages 795-803

  Williams, Sarah V ^a   Hurst, Carolyn D ^a   Knowles, Margaret A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; HYBRID PROTEIN; PHOSPHOLIPASE C GAMMA1; PROTEIN; TRANSFORMING ACID COILED COIL 3; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; BLADDER CANCER; CELL LOSS; CONTROLLED STUDY; DNA EXTRACTION; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE REARRANGEMENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; MICROTUBULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TUMOR CELL LINE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL ADHESION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOME BREAKPOINTS; CHROMOSOMES, HUMAN, PAIR 4; FIBROBLAST GROWTH FACTOR 1; HUMANS; MICE; MICROFILAMENT PROTEINS; MICROTUBULE-ASSOCIATED PROTEINS; NIH 3T3 CELLS; ONCOGENE PROTEINS, FUSION; POINT MUTATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; SEQUENCE ANALYSIS, DNA; TRANSLOCATION, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 84873045850     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds486     Document Type: Article

References (25)

1. di Martino, E., Tomlinson, D.C. and Knowles, M.A. (2012) A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv. Urol., 2012, 429213.
2. Lamont, F.R., Tomlinson, D.C., Cooper, P.A., Shnyder, S.D., Chester, J.D. and Knowles, M.A. (2011) Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br. J. Cancer, 104, 75-82.
3. Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K. et al. (2009) Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice. J. Clin. Invest., 119, 1216-1229.
4. Tomlinson, D.C., Hurst, C.D. and Knowles, M.A. (2007) Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene, 26, 5889-5899.
5. Bernard-Pierrot, I., Brams, A., Dunois-Lardé, C., Caillault, A., de Medina, S.G.D., Cappellen, D., Graff, G., Thiery, J.P., Chopin, D., Ricol, D. et al. (2006) Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis, 27, 740-747.
6. Guagnano, V., Furet, P., Spanka, C., Bordas, V., Le Douget, M., Stamm, C., Brueggen, J., Jensen, M.R., Schnell, C., Schmid, H. et al. (2011) Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin- 1-yl)-phenylamin o]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem., 54, 7066-7083.
7. Tomlinson, D.C., L'Hôte, C.G., Kennedy, W., Pitt, E. and Knowles, M.A. (2005) Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res., 65, 10441-10449.
8. Booth, D.G., Hood, F.E., Prior, I.A. and Royle, S.J. (2011) A TACC3/ch- TOG/clathrin complex stabilises kinetochore fibres by inter-microtubule bridging. EMBO J., 30, 906-919.
9. di Martino, E., L'Hôte, C.G., Kennedy, W., Tomlinson, D.C. and Knowles, M.A. (2009) Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. Oncogene, 28, 4306-4316.
10. Hart, K.C., Robertson, S.C. and Donoghue, D.J. (2001) Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation. Mol. Biol. Cell, 12, 931-942.
11. Singh, D., Chan, J.M., Zoppoli, P., Niola, F., Sullivan, R., Castano, A., Liu, E.M., Reichel, J., Porrati, P., Pellegatta, S. et al. (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science, 337, 1231-1235.
12. Hood, F.E. and Royle, S.J. (2011) Pulling it together: The mitotic function of TACC3. Bioarchitecture, 1, 105-109.
13. Schneider, L., Essmann, F., Kletke, A., Rio, P., Hanenberg, H., Wetzel, W., Schulze-Osthoff, K., Nurnberg, B. and Piekorz, R.P. (2007) The transforming acidic coiled coil 3 protein is essential for spindle-dependent chromosome alignment and mitotic survival. J. Biol. Chem., 282, 29273-29283.
14. Schmidt, S., Schneider, L., Essmann, F., Cirstea, I.C., Kuck, F., Kletke, A., Janicke, R.U., Wiek, C., Hanenberg, H., Ahmadian, M.R. et al. (2010) The centrosomal protein TACC3 controls paclitaxel sensitivity by modulating a premature senescence program. Oncogene, 29, 6184-6192.
15. Yao, R., Natsume, Y., Saiki, Y., Shioya, H., Takeuchi, K., Yamori, T., Toki, H., Aoki, I., Saga, T. and Noda, T. (2012) Disruption of Tacc3 function leads to in vivo tumor regression. Oncogene, 31, 135-148.
16. Jung, C.K., Jung, J.H., Park, G.S., Lee, A., Kang, C.S. and Lee, K.Y. (2006) Expression of transforming acidic coiled-coil containing protein 3 is a novel independent prognostic marker in non-small cell lung cancer. Pathol. Int., 56, 503-509.
17. Duncan, C.G., Killela, P.J., Payne, C.A., Lampson, B., Chen, W.C., Liu, J., Solomon, D., Waldman, T., Towers, A.J., Gregory, S.G. et al. (2010) Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget, 1, 265-277.
18. Bargo, S., Raafat, A., McCurdy, D., Amirjazil, I., Shu, Y., Traicoff, J., Plant, J., Vonderhaar, B.K. and Callahan, R. (2010) Transforming acidic coiled-coil protein-3 (Tacc3) acts as a negative regulator of Notch signaling through binding to CDC10/Ankyrin repeats. Biochem. Biophys. Res. Commun., 400, 606-612.
19. Partch, C.L. and Gardner, K.H. (2011) Coactivators necessary for transcriptional output of the hypoxia inducible factor, HIF, are directly recruited by ARNT PAS-B. Proc. Natl Acad. Sci. USA., 108, 7739-7744.
20. Angrisano, T., Lembo, F., Pero, R., Natale, F., Fusco, A., Avvedimento, V.E., Bruni, C.B. and Chiariotti, L. (2006) TACC3 mediates the association of MBD2 with histone acetyltransferases and relieves transcriptional repression of methylated promoters. Nucleic Acids Res., 34, 364-372.
21. Garriga-Canut, M. and Orkin, S.H. (2004) Transforming acidic coiled-coil protein 3 (TACC3) controls friend of GATA-1 (FOG-1) subcellular localization and regulates the association between GATA-1 and FOG-1 during hematopoiesis. J. Biol. Chem., 279, 23597-23605.
22. Millard, T.H., Dawson, J. and Machesky, L.M. (2007) Characterisation of IRTKS, a novel IRSp53/MIM family actin regulator with distinct filament bundling properties. J. Cell Sci., 120, 1663-1672.
23. Chen, G., Li, T., Zhang, L., Yi, M., Chen, F., Wang, Z. and Zhang, X. (2011) Src-stimulated IRTKS phosphorylation enhances cell migration. FEBS Lett., 585, 2972-2978.
24. Wang, K.S., Chen, G., Shen, H.L., Li, T.T., Chen, F., Wang, Q.W., Wang, Z.Q., Han, Z.G. and Zhang, X. (2011) Insulin receptor tyrosine kinase substrate enhances low levels of MDM2-mediated p53 ubiquitination. PLoS One, 6, e23571.
25. Chapman, E.J., Hurst, C.D., Pitt, E., Chambers, P., Aveyard, J.S. and Knowles, M.A. (2006) Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway. Oncogene, 25, 5037-5045.